Corporate Presentation

NASDAQ: HALO

May 2023

Forward Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's financial outlook for 2023) and expectations for profitability, revenue (including expectations for future royalties, milestones and product sales), EBITDA and earnings-per-share, and the Company's plans to repurchase shares under its share repurchase program and to potentially expand the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery and potential to decrease treatment burden and decrease healthcare costs. Forward-looking statements regarding the Company's ENHANZE® business may include potential growth driven by our partners' development and commercialization efforts (including anticipated new clinical trial starts, study readouts, PDUFA dates, ENHANZE® product approvals and launches and the timing related to these events), projections for future sales revenue and market share of our collaborators' products, potential new or expanded ENHANZE® collaborations, collaborative targets and indications for ENHANZE® products, co-formulation intellectual property and the Company's plans to develop a high volume auto-injector and new formulations of its API for longer intellectual property protection. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners and product sales), expenditures and costs, unexpected delays in the execution of the Company's share repurchase program or planned platform expansion, unexpected results or delays in the growth of the Company's ENHANZE® business (including as a result of unexpected conversion rates), obtaining new co-formulation intellectual property, or in the development, regulatory review or commercialization of new formulations of the Company's API or its partners' ENHANZE® products, unexpected delays in the Company's plans to develop a high volume auto-injector, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Non-GAAP Financial Measures:
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports EBITDA, adjusted EBITDA and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, share-based compensation expense and the effects of any discrete income tax items.

What We Do: License Drug Delivery Platforms to Partners, and Commercialize Specialty Products

Drug Delivery Platform Technologies

ENHANZE®

Commercially-Validated

Sub-Cutaneous Delivery

- 5 globally-approved partnered products
- Approved in 100+ countries
- ~700,000 patients have received ENHANZE®- enabled treatments

Auto-Injectors

Commercialized & development stage devices for broad application



Commercial Portfolio

Specialty Products

Hylenex® recombinant (hyaluronidase human injection)

XYOSTED® (testosterone enanthate) injection (C III)

TLANDO® (testosterone undecanoate) (C III)

Halozyme 2023 Growth Opportunities

New Potential Royalty Revenue Opportunity

- 2 Potential ENHANZE® SC Approvals in 2023
- 2 Additional Potential ENHANZE® SC Approvals by 2025

Clinical Advancement of Partner Products with ENHANZE®

- SC Ocrelizumab Phase 3 Data Expected in 2023
- argenx CIDP Phase 3 Data Expected in July 2023

New Partnership Opportunities

- One ENHANZE® Deal
- One High Volume Auto-Injector plus ENHANZE® Deal
- One Small Volume Auto-Injector Deal

Halozyme: Delivering Strong & Durable Growth

01 **Differentiated Growth Platforms**

02 >$1B ENHANZE® Opportunity

03 Specialty Product Opportunity

04 Durable Revenue and Financial Strength

The World Needs More Subcutaneous Large and Small Molecule Drug Delivery

Halozyme

Potential benefits for **Patients and Caregivers**

- **Decreased treatment burden**
  - Hours to minutes[2]
- **Improved patient experience**
  - Prefer SC vs. IV[1]
  - Optionality[5]
- **Lower infusion related reactions IRRs**[3,4,6]

Potential benefits for **Healthcare System (providers, nurses, pharmacists, payers)**

- **Potential to decrease healthcare costs:**
  - Less use of more costly hospital/ infusion centers[7]
  - Greater patient throughput for clinics
  - Decrease HCP time in administration[7]
  - Decreased drug wastage[8] (fixed vs. weight-based dosing)

Sources: [1] Pivot X, Gligorov J, Müller V, et al. "Patients' Preference for SC vs. IV", Annals of Oncology, 2014; 3:4. [2] Stephen P. Knowles, Marie A. Printz, David W. Kang, Michael J. LaBarre & Renee P. Tannenbaum (2021): Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery, Expert Opinion on Drug Delivery, DOI: 10.1080/17425247.2021.1981286. [3] Chari A, Nahi H, Mateos M-V, et al. Presented at: ASH Annual Meeting; Dec 9-12, 2017; Atlanta, GA. [3] Lancet Haematol. "Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicenter, open-label, non-inferiority, randomised, phase 3 trial"; 2020. [4] Wasserman RL, Melamed I, Stein M, et al. Meeting of the ACAAI; Nov 3-8, 2011; Boston, MA. [5] Rummel M, Kim TM, Aversa F, et al. "Preference for subcutaneous or intravenous administration", Annals of Oncology 28 , no 4 (2016): 836,838. [6] Chari A, Nahi H, Mateos M-V, et al. Presented at: ASH Annual Meeting; Dec 9-12, 2017; Atlanta, GA. [7] Sanchez, ClinicoEconomics and Outcomes Research: 2019: 695. [8] Hendrikx,"Fixed Dosing of Monocolonic Antibodies in Oncology" The Onoclogist 2017; 22; 1212-122.

ENHANZE®: Patented, De-risked, Commercial Platform Technology Enabling Rapid, High Volume Subcutaneous Delivery of IV Drugs



What it does: ENHANZE® creates temporary space for SC fluid dispersion which returns to normal; reduces backpressure

ENHANZE®

Uniquely enables rapid SC delivery
- 5-15mL over 2-5 minutes
- 300-600mL at 5 mL/min

Decreased injection site swelling and induration

Aids absorption leading to increased bioavailability versus subcutaneous without ENHANZE®[1]

Potential for decreased systemic infusion related reactions

[1] Morcos International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 7/2013 (537-548)

Established Drug Delivery Leadership:
5 Globally-Approved Partner Products, Robust and Diverse Pipeline

5
Globally-Approved Products

100+
Countries

~700,000
Patients have received ENHANZE®–enabled SC products

2 Partner Products in Regulatory Review

4 Partner Products in Phase 3

8 Partner Products in/ completed Phase 1

Multiple Target Opportunities Open for ENHANZE®

Therapeutic Area	Targets Taken Exclusively	Available IV High Volume Targets*
Oncology	9	23
CNS	1	10
Hematologic	1	11
Autoimmune Diseases	4	8
Cardiovascular/Metabolic	0	6
Infectious Disease	5	5
TOTAL	**20**	**63**

Sources: Evaluate Ltd and Citeline Pharmaprojects

Halozyme Differentiated Proprietary and Partner Small Volume Auto-Injectors (SVAI),Commercially Available and Widely Licensable

QuickShot® and BigShot® Auto Injectors

1 mL and 2.25 mL
SC or IM

XYOSTED® (testosterone enanthate) injection
idorsia
Selatogrel

VIBEX® Auto Injectors

1 mL
SC or IM

teva *Generic EpiPen*
teva *Generic Imitrex*
Otrexup® (methotrexate) injection for subcutaneous use
Assertio Holdings

VAI™ Auto Injectors

2.25 mL
SC or IM

ATRS-1902 (development stage)

Pen Injector Systems

1.5 mL and 3.0 mL
multi-dose, disposable

teva
Generic Forteo

8M units in 2022

NEW in 2023: ENHANZE® Plus Auto-Injector Facilitates 5mL to 10mL Auto-Injector

ENHANZE® + **Halozyme Auto-Injector Technology and Know How** ▶ **High Volume 5mL-10mL Auto-Injector**

- Creates space for fluid dispersion
- Reduces backpressure
- Reduces leakage to deliver planned dose

Customizable technology to meet partner needs

2023: Complete clinical feasibility testing

Halozyme: Delivering Strong & Durable Growth

01 Differentiated Growth Platforms

02 **>$1B ENHANZE® Opportunity**

03 Specialty Product Opportunity

04 Durable Revenue and Financial Strength

ENHANZE®: Durable Revenue Potential and Strong Future Growth Opportunities

Waves 1 & 2	Wave 3	Wave 4	Wave 5
5 Globally-Approved Products	4 Product Candidates	10 Product Candidates	
DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use | 1,800mg/30,000units PHESGO® pertuzumab/trastuzumab/hyaluronidase-zzxf SUBCUTANEOUS INJECTION HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Herceptin® trastuzumab MabThera SC Rituximab Subkutant	Launch Potential 2023-2025 Efgartigimod SC* Atezolizumab SC* Nivolumab SC Ocrelizumab SC	Launch Potential 2025-2027 8 in/completed Phase 1 2 in Phase 3	Launch Potential 2027+ New nominations from current and new partners
Revenue drivers 2021+	**Revenue drivers 2023-2025**	**Revenue drivers 2025-2027**	**Revenue drivers 2027+**

* Submitted for regulatory approval

ENHANZE®: A Royalty Growth Story

Projected Royalty Revenue Potential



2027 projection based on approved products and assumes global approval and launches of approximately 20 additional products in multiple indications. Includes projections for subcutaneous versions for targets not currently approved or commercially available. Assumes approved and under review co-formulation patents. *Includes auto-injector royalties. Innovator revenues based on Bloomberg or Evaluate Ltd analyst-based estimates when available. Conversion rates based on Halozyme internal projections. Royalty revenue projections includes targets selected and not yet disclosed. Projected royalty revenue is not risk-adjusted. Royalty rate mid-single digit range across all products

Wave 2: Launch Growth Drivers

DARZALEX SC/FASPRO® Share and Revenue Growth Continues

Total DARZALEX® Sales IV+SC ($B) [1]



DARZALEX FASPRO® Share of Total US DARZALEX® Sales[2]



[1] Analysts' consensus from Evaluate Ltd March 2023
[2] 2022 Symphony Health (subscription data presented with permission)

Wave 2: Launch Growth Drivers

Phesgo® Share and Revenue Growth Continues

Phesgo® Reduces Administration Time and Costs



- 85% of patients preferred Phesgo for Subcutaneous administration over the intravenous formulation of Perjeta and Herceptin
- Pivotal Ph I results for Phesgo OBI (on body injector) to enable patient self-administration expected in H2

Phesgo® Global Conversion Rate[1]



[1]Roche's First Quarter 2023 Results

*Phesgo® conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries).

Wave 3: Four Potential Launches 2023-2025

Products			Disease Areas	Milestones	Potential Launch[1]
argenx	Efgartigimod	**IV APPROVED (gMG)**	gMyasthenia Gravis Other Indications	FDA PDUFA date extended to June 20, 2023 Additional SC with ENHANZE® indication data readouts projected in 2023	**2023** for gMyasthenia Gravis
Roche	Atezolizumab	**IV APPROVED**	Phase 3 in Non-Small Cell Lung Cancer[2]	FDA PDUFA date of September 15, 2023	**2023**
Roche	Ocrelizumab	**IV APPROVED**	Multiple Sclerosis	Phase 3 data readout projected in 2023	**2024**
Bristol Myers Squibb	Nivolumab	**IV APPROVED**	Clear Cell Renal Cell Carcinoma	Phase 3 ongoing	**TBD**

[1] Halozyme assessment based on company statements on pivotal data availability. Assumes 6 months for BLA submission filing and 10-month FDA review.
[2] Roche pursuing label for multiple indications

Wave 3: Developing SC Versions of Diverse, Blockbuster Products

Parent Products Projected at >$35B in 2028[1]

Efgartigimod

First-in-class anti-FcRn

Approved as IV for Generalized Myasthenia Gravis

Potential to address unmet need in ~15 indications

Analysts' projections: ~$7.4B in 2028[1]

Atezolizumab

Leading anti-PDL1

Currently approved in 5 cancer types

Analysts' projections: ~$7.7B in 2028[2]

Nivolumab

Currently approved in 10+ cancer types

Analysts' projections: ~$12.9B in 2028[2]

Ocrelizumab

Number 1 Multiple Sclerosis treatment US and EU 5[3]

Widely studied with long term data

Analysts' projections: ~$7.4B in 2028[2]

[1] Analysts' consensus from Evaluate Ltd March 2023
[2] Analysts' consensus from Evaluate Ltd April 2023
[3] Roche's First Quarter 2023 Results

Efgartigimod SC: Potential to Transform Treatment Approach for Patients with Autoimmune Diseases

Efgartigimod sales **~$7.4B** in 2028, with significant ex-US sales[1]

Extensive SC Development and Large Opportunity

	SC	IV	SC status	WW Total Opportunity Projection 2028[1]
gMyasthenia Gravis	✓	✓	US PDUFA date: June 20, 2023 Submitted EMA	$2.2B
CIDP	✓		Phase 3 SC data: July 2023	$2.7B
ITP	✓	✓	Positive IV data Phase 3 SC data: Q4 2023	$0.9B
Pemphigus	✓		Phase 3 SC data: Q4 2023	$0.6B
Bullous Pemphigoid	✓		Phase 2/3 ongoing	$0.8B
Myositis	✓		Phase 2/3 ongoing	

ENHANZE® Potential Impact

- Rapid, SC injection ~1 minute versus 60 minutes for IV
- May facilitate penetration into early disease patients

[1] Analysts' consensus and projections from Evaluate Ltd March 2023

Atezolizumab SC: Potential to Reduce Treatment Burden, Help Alleviate Infusion Clinic Capacity Constraints

Total Atezolizumab sales **~$7.7B** in 2028, with significant ex-US sales[1]

SC Opportunity

TECENTRIQ Monotherapy +/- Oral Therapy	TECENTRIQ IV Combination Indications
FDA Approved Indications	**FDA Approved Indications**
Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer
Melanoma	Hepatocellular Cancer
Alveolar Soft Part Sarcoma	Small Cell Lung Cancer

ENHANZE® Potential Impact

- EU and US filing with PDUFA date of September 15, 2023, seeking approval across all indications
- Rapid SC injection over 7 minutes versus 30-60 mins IV
- Potential to reduce healthcare utilization and reduce cost in monotherapy and combination setting

[1] Analysts' consensus and projections from Evaluate Ltd April 2023

Nivolumab SC: Potential to Reduce Treatment Burden, Help Alleviate Infusion Clinic Capacity Constraints

Total Nivolumab sales **~$12.9B** in 2028, with significant ex-US sales[1]

ENHANZE®
Potential Impact

- Phase 3 SC Opdivo monotherapy studies ongoing
  - Renal Cell Carcinoma
- Phase 3 Nivolumab plus Relatlimab SC fixed dose combination in melanoma study initiated

[1] Analysts' consensus and projections from Evaluate Ltd April 2023

Ocrelizumab SC: Meaningful Reduction in Administration and Observation Schedule Adds to Competitive Profile

Ocrelizumab sales **~$7.4B** in 2028, with significant ex-US sales[1]

ENHANZE®
Potential Impact

ENHANZE® could reduce administration and observation schedule to 60 mins for first 2 doses and **10 mins for all subsequent doses**[2]



- Ph III (OCARINA II) evaluating subcutaneous Q6M dosing of Ocrevus for non-inferiority vs Ocrevus IV in RMS & PPMS with data expected in 2023
- Increases potential for Ocrevus use in centers with IV capacity constraints
- Final dose monitoring requirements for SC subject to regulatory review

[1] Analysts' consensus and projections from Evaluate Ltd April 2023
[2] Roche Presentation
[+] Expected but may vary based on clinical results and regulatory review
RMS=relapsing multiple sclerosis; PPMS=primary progressive MS; Q6M=dosing every 6 months

Wave 4: Multiple Potential Launches

Analysts' Consensus Revenue For All Parent Products in 2028: >$60B[1]

ONCOLOGY	IMMUNE/ AUTOIMMUNE	HIV
Nivolumab+Relatlimab (BMS) **IV APPROVED** **SC in Phase 3**	Teprotumumab-trbw (Horizon) **IV APPROVED**	N6LS bnAb (ViiV)
Amivantamab (Janssen) **IV APPROVED** **SC in Phase 3**	ARGX-117 (argenx)	Cabotegravir (ViiV) **Oral and IM APPROVED**
	TAK-881 (Takeda)	Rilpivirine (Janssen) **Oral APPROVED**

In or have completed Phase 1

[1] Analysts' consensus for Wave 1-4 products from Evaluate Ltd. March and April 2023 excluding, ARGX-117 (argenx), undisclosed (Roche), undisclosed (Chugai), TAK-881 (Takeda) and N6LS(Viiv)

Table excludes Roche undisclosed target, Chugai undisclosed target, each in Phase 1

Halozyme: Delivering Strong & Durable Growth

01 Differentiated Growth Platforms

02 >$1B ENHANZE® Opportunity

03 **Specialty Product Opportunity**

04 Durable Revenue and Financial Strength

Testosterone Replacement Therapy Portfolio:
Targeting to Generate >$100M XYOSTED Revenue in 2023

Halozyme

FOCUS	FOCUS	OPPORTUNITY
XYOSTED® (testosterone enanthate) injection Ⓒ	TLANDO® (testosterone undecanoate) Ⓒ	~8.5M TRX prescribed for testosterone replacement therapy in 2022
Once-a-week dosing	2X/daily oral administration	Growing ~5% YOY
Virtually painless subcutaneous injection using auto-injector technology	First oral TRT without titration requirement	Switch strategy from IM and gels
21 Orange Book-listed patents extending to 2038		**Each 1% share gain ~$20M in net sales**
Launched November 2018	*Launched June 2022*	

Halozyme: Delivering Strong & Durable Growth

01 Differentiated Growth Platforms

02 >$1B ENHANZE® Opportunity

03 Specialty Product Opportunity

04 **Durable Revenue and Financial Strength**

Halozyme Strategic and Capital Allocation Priorities

Invest to Maximize Revenue Growth and Durability

- ENHANZE®
- Auto-injector innovation
- Commercial opportunity

Continue to Return Capital to Shareholders

Second Plan: December 2021

$750M 3-year share buyback

- $500M completed through March 2023
- $150M completed in 1Q 2023

Identify Opportunities for External Growth

- Continue to evaluate opportunities to accelerate and extend revenue

2023: Projected Acceleration in Royalty Generating Products



2023 Financial Guidance Highlights

	2022	2023	
Total Revenue	$660.1M	**$815M - $845M**	• 23-28% YoY growth • Product Sales expected to increase due to full year Antares contribution and increasing ENHANZE® API demand • Total collaboration revenue expected to not exceed the levels in 2022, milestones to begin the second quarter
Royalty Revenue	$360.5M	**$445M - $455M**	• 23-26% YoY growth • Continued DARZALEX® and Phesgo® uptake and full year device royalty contribution
EBITDA	$314.5M	**$415M - $440M**	• 32-40% YoY growth • Excludes impact of amortization costs in 2023 related to the Antares acquisition
Non-GAAP Diluted EPS	$2.21	**$2.50 - $2.65**	• 13-20% YoY growth • Excludes impact of future share repurchases

Appendix

ENHANZE® Partner Product Development Pipeline

Wave 3 Pipeline

Current Program/Product	Indications	Phase 1	Phase 2	Phase 3	Filed
Wave 3					
Efgartigimod (argenx)	gMG				
Atezolizumab (Roche)	NSCLC				
Ocrelizumab (Roche)	Multiple sclerosis				
Nivolumab (BMS)	RCC				
Efgartigimod (argenx)	CIDP				
Efgartigimod (argenx)	Immune thrombocytopenia				
Efgartigimod (argenx)	Pemphigus				
Efgartigimod (argenx)	Bullous Pemphigoid (BP)				
Efgartigimod (argenx)	Myositis				

ENHANZE® Partner Product Development Pipeline

Wave 4 Pipeline

Current Program/Product	Indications	Phase 1	Phase 2	Phase 3	Filed
Wave 4					
Amivantamab (Janssen)	Solid malignancies				
Nivolumab+Relatlimab (BMS)	Melanoma				
ARGX-117 (argenx)	Multifocal motor neuropathy				
Teprotumumab-trbw (Horizon)	Thyroid Eye Disease				
Rilpivirine (Janssen)	HIV				
Undisclosed (Roche)	Undisclosed				
TAK-881 (Takeda)	Immune				
Cabotegravir (ViiV)	HIV				
N6LS bnAb (ViiV)	HIV (treatment)				
Undisclosed (Chugai)	Undisclosed				

GAAP to Non-GAAP Reconciliation: EBITDA

$ U.S. in Millions, except EPS (unaudited)

	Twelve Months Ended December 31, 2022
GAAP Net Income	**$ 202**
Adjustments:	
Investment and other income	$ (1)
Interest expense	$ 17
Income tax expense	$ 47
Depreciation and amortization	$ 50
EBITDA	**$ 315**

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

GAAP to Non-GAAP Reconciliation: Diluted EPS

$ U.S. in Millions, except EPS (unaudited)

	Twelve Months Ended December 31, 2022
GAAP Diluted EPS	**$ 1.44**
Adjustments:	
Inducement expense related to convertible notes	0.02
Share-based compensation	0.17
Amortization of debt discount	0.06
Amortization of intangible assets	0.31
Transaction costs for business combinations[1]	0.16
Severance and share-based compensation acceleration expense[2]	0.16
Amortization of inventory step-up at fair value[3]	0.06
Realized loss from marketable securities[4]	0.01
Income tax benefit[5]	—
Income tax effect of above adjustments[6]	(0.17)
Non-GAAP Diluted EPS	**$ 2.21**

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

(1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the Antares acquisition.

(2) Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.

(3) Amount related to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.

(4) Amount represents realized loss from the sale of our marketable securities to finance the acquisition of Antares.

(5) In the third quarter of 2021, the Company recognized a non-cash tax benefit of approximately $142 million related to the release of substantially all of its valuation allowance against its deferred tax assets.

(6) Estimated income tax effect of the Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration of any valuation allowance.

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.